Key result
IL-1β induces the adaptive reprogramming of endogenous human cardiac fibroblasts into cells expressing the T-helper marker CD4 and other immune features during fibrotic remodeling.
Why the study?
The source and roles of fibroblasts and T-cells during maladaptive remodeling and myocardial fibrosis in pulmonary arterial hypertension have been debated.
IL-1β induces immune-competency in human cardiac fibroblasts, suggesting that modulating the fibroblast secretome could be a therapeutic approach for PAH and other fibrotic diseases.
May implicate CD4+ fibroblasts in PAH RV fibrosis; leaves open their therapeutic targeting pending validation.
The source and roles of fibroblasts and T-cells during maladaptive remodeling and myocardial fibrosis in the setting of pulmonary arterial hypertension (PAH) have been long debated. We demonstrate, using single-cell mass cytometry, a subpopulation of endogenous human cardiac fibroblasts expressing increased levels of CD4, a helper T-cell marker, in addition to myofibroblast markers distributed in human fibrotic RV tissue, interstitial and perivascular lesions in SUGEN/Hypoxia (SuHx) rats, and fibroblasts labeled with pdgfrα CreERt2/+ in R26R-tdTomato mice. Recombinant IL-1β increases IL-1R, CCR2 receptor expression, modifies the secretome, and differentiates cardiac fibroblasts to form CD68-positive cell clusters. IL-1β also activates stemness markers, such as NANOG and SOX2, and genes involved in dedifferentiation, lymphoid cell function and metabolic reprogramming. IL-1β induction of lineage traced primary mouse cardiac fibroblasts causes these cells to lose their fibroblast identity and acquire an immune phenotype. Our results identify IL-1β induced immune-competency in human cardiac fibroblasts and suggest that fibroblast secretome modulation may constitute a therapeutic approach to PAH and other diseases typified by inflammation and fibrotic remodeling.
No takes yet. Share an insight, caveat, or question.
Siamwala et al. (2023) studied Pulmonary Arterial Hypertension and Cardiac Fibrosis. Interleukin-1β (IL-1β) vs. Vehicle was evaluated on Expression of CD4 and immune features in cardiac fibroblasts. IL-1β induces the adaptive reprogramming of endogenous human cardiac fibroblasts into cells expressing the T-helper marker CD4 and other immune features during fibrotic remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: